Vasomedical Turns To Angina Market Following Negative CMS Decision

Vasomedical is counting on a two-pronged strategy of increasing Luminair EECP external counterpulsation therapy sales for angina treatment and decreasing expenses to stay afloat following a detrimental CMS proposed decision